Is your Biomarker Strategy Up-to-Date?
Is your Biomarker Strategy Up-to-Date?
Research on neurological biomarkers is a very dynamic field. The recent FDA approval of a diagnostic test measuring the Amyloid-beta 1-42 / 1-40 ratio in CSF for Alzheimer's disease, or the breakthrough device status granted to a blood test measuring NfL levels in Multiple Sclerosis are a clear illustration of this trend.
At Active Biomarkers, we have implemented methods to detect neurological biomarkers in both CSF AND Blood matrices, using ultrasensitive immunoassays when required.